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recession and the IPHA agreement on the rate of positive reimbursement made by 
the NCPE. We also tested whether the new agreement had an impact on the time-
to-reimbursement using a linear regression model. Results: The results of the 
logit model suggest that neither the economic recession nor the agreement had 
any statistically significant impact on the probability of reimbursement. However, 
there was some evidence that the time-to-reimbursement was reduced after the 
agreement (p< 0.10). ConClusions: Although the analysis suggests that these two 
events had no impact on the rate of reimbursement it is possible that the reimburse-
ment price of new drugs may have decreased over this period which could have 
facilitated reimbursement. Unfortunately, details of the final price of medicines are 
not always known in the Irish system and it is therefore not possible to test this 
hypothesis using currently available data. Our analysis of time-to-reimbursement 
suggests that the new agreement may have satisfied one of its main objectives in 
getting new medicines onto the market sooner.
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objeCtives: Offering a standardized HTA process model through economic evalu-
ation of IDTs in the Turkish health care system. Methods: Current regulations on 
evaluation of innovative drug technologies through the reimbursement process are 
defined via a process flow scheme. A stepwise model is proposed to cover a stand-
ardized HTA system within the economic evaluation through an independent HTA 
body (Model HTA Authority). Results: In the current system, economic evaluation 
content of a reimbursement application dossier is evaluated by Social Security 
Institution (SSI) through Technical and Main Commissions respectively. However 
this evaluation process is not standardized with respect to main variables such as 
scientific methodologies, timelines and responsibilities. This study offers a model, 
which initiates a re-defined application step for economic evaluation content 
of a IDT reimbursement dossier; parallel application to SSI and an independent 
HTA body (Model HTA Authority). Therefore, the Main Commission in SSI will be 
able to combine a general evaluation from the Technical Commission and an HTA 
report of the IDT by an independent HTA body. These reports will be available to 
owners of reimbursement applications until announcement of a final decision of 
SSI, and will become publicly available afterwards. ConClusions: IDTs are not 
involved in a standardized HTA process in the current Turkish health care system. 
However, pharmacoeconomic analysis reports are requested by SSI for reimburse-
ment applications of IDTs. This study offers a model, which includes a standard-
ized HTA process for IDT in the Turkish health care system. Applicability of this 
model may be tested through pilot projects and further steps may be defined for 
further excellence.
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objeCtives: To identify, from a private payer’s perspective, the required elements 
to include in a pharmacoeconomic model and a budget impact analysis and com-
pare them to that of the public payers’ requirements. The secondary objective was 
to determine the preferred components to present in a submission regarding pri-
vate payers. Methods: A survey was sent to 21 submission reviewers from 14 
private insurance companies offering drug reimbursement, using an online sur-
vey builder, KwikSurveys. The survey included 15 questions divided in 5 sections: 
General information, Clinical information, Pharmacoeconomic evaluation, Budget 
impact analysis and General appreciations. Results: Nine reviewers from eight 
different companies, which represent 80% of the Canadian private payer market 
shares, responded to the survey. Results showed that 67% of participants follow the 
Canadian Agency for Drugs and Technologies in Health (CADTH) guidelines for eco-
nomic evaluations. 88% of participants prefer a cost-effectiveness evaluation, while 
75% prefer a cost-benefit evaluation. 100% of the participants would like direct drug 
costs and the indirect costs related to loss of productivity due to reduced working 
capacity to be included in the pharmacoeconomic model. 75% would like the costs 
to employer to hire and train replacement worker, the costs of premiums paid to, 
as well as benefits received from, private insurers to also be included in the model. 
63% of the participants would like to see a population data-based model for their 
budget impact analysis. Similarly, 63% of the participants prefer a time horizon 
of 3 years for the budget impact analysis. ConClusions: The parameters to be 
considered in a submission sent to private payers are different from public payers’ 
requirements. The perspective of the pharmacoeconomic model should be that of 
a private payer and the budget impact analysis should only consider a population 
covered by private payers.
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objeCtives: Market access for innovative new technologies can be complex 
and time consuming. As cost-containment pressures in the European Union (EU) 
intensify, evidentiary hurdles to justify new point-of-care (POC) tests continue to 
grow. Decentralized health care decision making can also be a significant hurdle. 
This study aimed to characterize the process and identify challenges for Health 
Technology Assessment (HTA), pricing, reimbursement, and market access for a 
new POC test in the EU-5 countries. Methods: We conducted desktop research of 
dence. Both organizations reached the same assessment regarding clinical benefit 
in only 13 cases (52%). ConClusions: AMNOG implements a more rigorous process 
with respect to clinical evidence assessment compared to SMC. All AMNOG deci-
sions are positive; however final prices may resemble generic prices for products 
that demonstrate low additional benefit (“Festbetragsgruppen”). In comparison, 
a negative decision by SMC warrants re-submission and re-assessment of the set 
price for successful drug reimbursement. Orphan drugs are assessed as normal 
products in Scotland and may be rejected on the grounds of economic evidence, 
while in Germany the additional benefit is presumed and price negotiation starts 
automatically. Furthermore, the SMC assessment process starts later than the 
AMNOG process.
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While pharmaceutical sales in mature economies are declining, in emerging mar-
kets they have been expanding rapidly, with growth rates in double figures. Here we 
focus on market access in BRIC (Brazil, Russia, India and China) which together rep-
resent just over 40% of the world population.objeCtives: To identify the processes 
and key stakeholders involved in gaining market access in BRIC; to assess the impor-
tance of health technology assessment (HTA) in gaining reimbursement in these 
countries; to identify opportunities and challenges to market access. Methods: 
A review was conducted to identify the current processes and key stakeholders in 
market access in the BRIC countries and to identify favourable and unfavourable fac-
tors to market access. Results: The licensing and reimbursement processes vary 
in the BRIC countries. Brazil follows processes similar to those in Western Europe, 
including HTA and public consultation as part of the reimbursement application. In 
China, the licensing process can take 4-6 years, though fast-tracking for innovative 
drugs has recently been introduced. Russia, China and India do not yet rely on HTA 
for reimbursement decisions. In India plans to use “pharmacoeconomic principles” 
in setting prices of new molecules have been announced. Opportunities in all these 
countries result from increasing affluence and life expectancy and the diseases 
associated with these. Some challenges to market access are: poor IP protection; 
protectionist measures; compulsory licensing; drive to use generics or biosimilars, 
often produced locally; price controls; variable health insurance/NHS coverage; 
and limited budgets for prescription drugs. ConClusions: HTA is now common 
practice in Brazil, but not yet in Russia, India or China. Although demand for new 
drugs is increasing in these markets, protectionism measures, competition from 
generics and budget constraints due to the increased burden and requirement for 
new high priced drugs present a challenge when accessing the pharmaceutical 
market in BRIC countries.
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objeCtives: The gold-standard pivotal trial design has three arms with experi-
mental medicine, placebo and active control however, often marketing authorisa-
tion is granted on placebo controlled (PLAc) trial(s). While PLAc trials are often 
still acceptable to the European Clinical Trials Directive and European Medicines 
Agency (EMA), they are less acceptable to Health Technology Assessment (HTA) 
bodies. The latter request an (in)direct comparison vs. the relevant active 
comparator(s) (AC) to demonstrate the added value of existing standard of care. 
We have investigated the hurdles encountered during HTA assessments for those 
drugs with marketing authorization based solely on PLAc studies. Methods: We 
identified those drugs approved since 2010 by EMA based only on PLAc trials. We 
then reviewed the HTA assessments for these drugs in France (HAS), Germany 
(G-BA) and the UK (NICE and SMC) and compared these HTA assessments to others 
where the trial included an AC. Results: Applications for 41 (45 indications) of the 
220 drugs approved by EMA between 2010 and end of 2012 were based exclusively 
on PLAc trials. The number of indications already assessed and recommended 
(percentage) by HTA bodies are 19 and 11 (58%) for NICE, 33 and 18 (55%) for SMC, 
24 and 20 (83%) for HAS, and 18 and 12 (67%) for G-BA. When compared to all 
HTAs irrespective of comparator being placebo or AC assessed since 2010, lack of 
an AC seemed to have no impact in HAS (83% vs 75% favorable opinion among all 
assessments) and G-BA (67% vs 58%) assessments but had a negative impact on 
SMC (55% vs 85%) and NICE (58% vs 64%) recommendations. ConClusions: The 
impact of no direct comparison with an AC varies across countries. The analysis 
seems to indicate that in absence of head-to-head data HTA agencies will accept 
indirect evidence against the right AC.
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objeCtives: To assess the impact of the Irish economic recession (September, 2008) 
and the Irish Pharmaceutical Healthcare Association agreement (IPHA; November, 
2012) on the probability of reimbursement decided by the National Centre for 
Pharmacoeconomic Evaluation (NCPE). We also aim to test whether the new IPHA 
agreement reduced the time-to-reimbursement for new medicines in the General 
Medical Services (GMS) and High Tech Drug Scheme (HTDS). Methods: A database 
of all NCPE decisions since 2006 to present was compiled from publically available 
NCPE decision reports and a logistic model was used to test the occurrence of the 
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objeCtives: During 1991-2000, Japan contribution to the top basic and clinical sci-
ence journals was less than 1% and 3%, respectively. The objective of this study was 
to compare the Japanese representation in 7 major general medicine journals and 
6 basic science journals between the years 1991-2000 and 2001-2010. Methods: 
Retrospective observational study. We measured the frequency of journal article 
publications in PubMed from Japan in both seven high-impact general medical and 
internal medicine journals and six high-impact basic science journals using Boolean 
operators to connect name of the journal, year of publication and corresponding 
authors’ affiliation with different universities, cities and places in Japan. Results: 
Japan represented 0.66% (260/39,255) and 0.74% (265/36,038) of journal articles in 7 
of the top general medicine journals during 1991-2000 and 2001-2010, respectively. 
In contrast, the respective representation in 6 of the top basic science journals was 
2.51% (849/33,779) and 3.60% (1364/37,908), respectively. Overall, we observed that 
the proportion of Japan-originated articles published in the top general medicine 
journals during 2001-2010 remained unchanged compared to 1991-2000 (P= 0.255). 
However, the Japanese representation in basic science journals during 2001-2010 
increased significantly compared to 1991-2000 (P< 0.001). Japanese representation in 
basic science journals had an upward trend during the 1991-2000 period (P< 0.001) 
but remained flat during 2001-2010 (P= 0.177). In contrast, the trend of Japanese 
representation in general medicine journals remained flat during the period of 
1991-2000 (P= 0.273) but exhibited a marginally downward trend during 2001-2010 
(P= 0.073). ConClusions: Overall, the Japanese representation in top general 
medicine journals has remained negligible and unchanged over the last two dec-
ades. Representation in basic science journals remained unchanged during the 
time period of 2001-2010, although it had shown an upward trend during the years 
1991-2000. Interventional measures are needed to address these trends.
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objeCtives: Prompt access to effective health care is a priority in the develop-
mental agenda of Ghana yet only 20% of people who actually need health care have 
it. Evidence on the determinants of prompt access to health care in these CHPS 
programme is woefully inadequate. The study sought to assess the factors that 
influence prompt access to health care in CHPS settings. Methods: A descriptive 
cross sectional study was conducted in 2011 with 230 respondents within the CHPS 
zones of Bawjiase Sub-district, Central region of Ghana. Data was collected on using 
structured questionnaire and analyzed using SPSS version 19 software. Logistic 
regression was run to access the correlation of the determinants on prompt access 
to health care in CHPS settings at 95% confidence interval. Results: We identi-
fied that, factors which play a major role in prompt access of CHPS programme 
within the CHPS zones of Bawjiase sub - district include geographical accessibility 
(chi square = 33.57; p = 0.000) and service characteristics (chi square = 19.17; p = 
0.001). Economic accessibility however, had no influence (chi square = 123; p = 
0.975) on prompt access to CHPS programme. Factors which had strong influence 
on prompt access of CHPS programmes were age (chi square = 12.39; p = 0.015), 
sex (chi square = 15.25; p = 0.000), marital status (chi square = 31.56; p = 0.000), 
education level (chi square = 28.49; p = 0.000) and occupation (chi square = 33.56; p 
= 0.000). ConClusions: The study concludes that geographical proximity, service 
characteristics and individuals’ background factors influence prompt access to qual-
ity health care in rural CHPS setting.
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objeCtives: Astrological signs have been linked to numerous health problems, 
not only in pseudoscientific but also in high impact, peer-reviewed scientific lit-
erature. The aim of this study was to use a large prescription database to assess 
associations between astrological star signs and health problems. This study may 
demonstrate important statistical issues that arise when doing multiple compari-
sons. Methods: For this cross-sectional study, patient and drug data were collected 
from a large prescription database in The Netherlands. Patients were followed for 
one year, starting from their birthday in 2010. Outcomes were drug prescriptions 
for one of four health problems: cardiovascular disease, depression, erectile dys-
function in men and fertility problems in women. The “determinant” was patients’ 
astrological sign (based on Western-culture horoscope). Differences in prevalence 
rates between star signs were tested using logistic regression, adjusted for age 
and gender. Significance was set at P= 0.05. Results: Almost 300,000 persons were 
included for analysis. In our analysis, persons born under the star sign Aquarius 
were less likely to suffer from cardiovascular disease (P= 0.001), whereas patients 
born under Scorpio or Sagittarius were more likely (P= 0.011 and P= 0.017). There were 
no effects on depression or erection dysfunctions. Women born under Gemini were 
37% less likely to use fertility drugs (P= 0.016). ConClusions: This study found 
several associations between star signs and health problems, none of which had any 
biologic plausibility. Interestingly, datasets filled with randomly generated star sign 
data also resulted in significant findings. Multiple comparisons without prespeci-
fied hypotheses, biological plausibility and adjustments for familywise error rates, 
can lead to false-positive findings. Multiple comparisons are common in outcomes 
research, appropriate use of statistics therefore is important.
published literature, HTA reports, and third-party websites, to identify the critical 
path and data most valuable to reimbursement decision making. We conducted 26 
qualitative one-on-one interviews with payer decision makers in the EU-5: 12 key 
opinion leaders, 4 laboratory directors, and 10 academic health economists and HTA 
advisors. Results: Reimbursement is critical to rapid adoption of new technolo-
gies. There are multiple appropriate access pathways for various theatres of care 
(e.g., outpatient office/clinic, inpatient, emergency), all with varying requirements 
and value drivers. Payment for new diagnostic tests typically is handled regionally 
or locally; treating physicians and medical societies can influence these budget 
decisions. Shared financial agreements or risk-sharing scenarios may speed intro-
duction of a new POC test. Test reimbursement processes may differ for inpatient 
versus outpatient use. Currently, the evidence hurdle for a POC test is not as high 
as for prescription medicines. ConClusions: Market access for a POC test varies 
across and within countries; adequate data to meet decision makers’ needs is not 
well understood. No roadmap exists for navigation of the critical path for POC tests, 
and evidence requirements in the EU are not well established. Access for a POC test 
will be complex; regardless of pathway, decisions regarding reimbursement and 
adoption of new technology are diverse and dispersed across and within countries 
with varying levels of required evidence.
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objeCtives: With the advancing process of HTA in the Czech Republic question 
emerged such as what is the willingness to pay (WTP) for health and life as well 
as what is the general awareness of the national health care policy and health 
economics. So far all estimations of WTP were largely based on academic deduc-
tions, thus we adopted a previously published approach to estimate the empirical 
WTP. Methods: A total of 381 doctors of 15 specializations and 500 respondents 
from general population, both matching the CZ demography, were interviewed 
online. Doctors were asked directly to suggest reasonable WTP per equivalent of 
QALY. The general public was interview using the dichotomous double bounded 
choice method. The value of WTP, including 95% confidence interval, was deter-
mined using proc lifereg of the SAS system that allowed estimating averages for 
interval data. Optimal parametric extrapolation of the data was chosen based on 
the minimum value of Akaike’s information criterion (AIC). Results: Economics 
is the last criterion considered as important by doctors following the quality of life, 
clinical parameters and ethical/social aspects. Doctors not rejecting the concept 
of paying for health (28%) produced median of CZK 700,000 (EUR 27,129) to be an 
adequate payment for an extra year in full health, representing one QALY. General 
population suggested CZK 18.4 million (EUR 731,110) as an adequate WTP to be paid 
by the national health insurance fund, largely in contrast to only CZK 177,000 (EUR 
6859) as suggested for the pay-of-pocket WTP. ConClusions: The awareness about 
health economics and its methodology is rather low among doctors and general 
public. While those medical doctors who expressed understanding for the concept 
of WTP and QALY suggested a value similar with the implicit WTP of CZK 1,000,000 
(EUR 38,756) general public suggested extreme WTP from public budget, reflecting 
distant position of the public.
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objeCtives: Applications to run clinical trials in Europe have been falling 
since 2007. Costs, speed of approvals, and shortcomings of European Clinical 
Trial Directive (CTD) are commonly held responsible. However, there is no hard 
evidence on the actual weight of these factors, nor are policy recommenda-
tions typically founded on a research-based understanding of factors impact-
ing trial site selection. Indeed, borrowing from the rigour of its own discipline, 
medical policy decisions ought to be “evidence-based”. Methods: The SAT-EU 
StudyTM was an anonymous, cross-sectional Web-based survey designed to 
systematically assess factors impacting European clinical trial site selection. 
It explored 19 factors across investigator-, hospital-, and environment-driven 
criteria, and costs. It also surveyed perceptions of the European trial environ-
ment. Clinical Research Organizations (CROs), academic Clinical Trial Units 
(CTUs), and Industry were invited to respond. OUTCOME MEASURES: Primary: 
Weight assigned to each factor hypothesized to impact trial site selection and 
trial incidence; Secondary: Desirability of twelve European countries to run 
clinical trials Results: Responses were obtained from 485 professionals in 34 
countries: 49% from BioPharma, 40% from CTUs or CROs. Investigator-, environ-
ment-, and hospital-dependent factors were rated highly important, costs being 
less important (P< 0.0001). Within environment-driven criteria, pool of eligible 
patients, speed of approvals, and presence of disease-management networks 
were significantly more important than costs or government financial incentives 
(P< 0.0001). Germany, UK, and The Netherlands were rated the best trial markets 
(P< 0.0001). ConClusions: Fostering European clinical research does not require 
additional government spending or a revamping of the clinical trial cost structure. 
Rather, it requires greater visibility of centres of excellence and the harmonised 
national adoption of recently approved revisions to the CTD. Carefully crafted 
harmonization of approvals, including aligned hospital contracting, speedier trial 
authorization and greater visibility of disease networks may bring significantly 
more clinical research to Europe and stimulate growth.
